Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 211 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
Patents for C07D 211 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings (37,939)
05/2005
05/31/2005US6900244 Controlling lipid, cholesterol metabolism; anticholesterol agents
05/31/2005US6900228 Analgesics; side effect reduction
05/31/2005US6900218 Reducing oxidation stresses; central nervous system disorders; antiinflammatory agents
05/31/2005US6900214 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
05/31/2005US6900196 Serine protease inhibitors
05/26/2005WO2005047253A1 Melanocortin receptor agonists
05/26/2005WO2005047251A1 Melanocortin receptor agonists
05/26/2005WO2005047249A1 Benzylether amine compounds useful as ccr-5 antagonists
05/26/2005WO2005047230A1 Bis-cationic compounds and use thereof
05/26/2005WO2005046685A1 Substituted piperidines for the treatment of metabolic syndrome
05/26/2005WO2005046683A1 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
05/26/2005WO2005046612A2 Hydroxy piperidine derivatives to treat gaucher disease
05/26/2005WO2005046611A2 Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
05/26/2005WO2005046601A2 4-phenyl piperdine sulfonyl glycine transporter inhibitors
05/26/2005WO2005028438A9 Novel piperidine derivative
05/26/2005WO2004111000A3 Piperidyl derivatives and their use as tachykinin antagonists
05/26/2005US20050113580 2-(3-{3-[[2-chloro-3-(trifluoromethyl)benzyl](2,2-dephenylethyl)amino]propoxy}phenyl)-ethanol; agonists of the nuclear receptors, LXR alpha and LXR beta used to increase ABCA1, ABCG1, and apolipoprotein E expression and inhibiting cholesterol absorption
05/26/2005US20050113572 Reacting an allyl alcohol with a vinyl ether to form an aliphatic aldehyde; reducing N-[1-(methoxycarbonyl)-1-(dimethylphosphonato)methyl]-O-benzylcarbamate with a nitrogen heterocycle; dephosphonation with the aliphatic aldehyde; hydrogenation; amidation; protease inhibitors; industrial scale
05/26/2005US20050113450 method of sterilization, sanitation, antisepsis, and disinfection, includes applying antimicrobial compounds to a surface; e.g. 2-[(3-{[4-chloro(methyl)anilino]sulfonyl}benzoyl)amino]-5-(trifluoromethyl)benzoic acid
05/26/2005US20050113440 Compounds that modulate PPAR activity and methods for their preparation
05/26/2005US20050113424 E.g., 4-{3-[4-(3-{4-[amino(imino)methyl]phenoxy}propyl)-1-piperazinyl]propoxy}benzamidine; an antifungal agent with good pharmacokinetics and excellent antifungal action; side effect reduction such as nephrotoxicity; action to Mycomycetes
05/26/2005US20050113415 Promoting the activity of glucocerebrosidease by administering a reversible competitive inhibitor such as iminosugars, e.g. calysegnines, isofagomines,N-alkyl-deoxynojirimycins; lysosomal storage disorders
05/26/2005US20050113414 1-[1-((E)-1-Cyclooct-1-enyl)methylpiperidin-4-yl]-3-(3,4-dichlorophenyl)-urea; potent and selective modulators of CXCR3, a chemokine receptor; antagonists; treatment of conditions involving inappropriate T-cell trafficking; antiinflammatory, -arthritic agents, autoimmune diseases; antiallergens
05/26/2005US20050113383 For therapy of allergy, allergy-induced airway responses, congestion, hypotension, cardiovascular disease, hypotension, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastrointestinal tract, obesity, sleep
05/26/2005US20050113361 Amide derivatives as NMDA receptor antagonists
05/26/2005US20050113360 NMDA (N-methyl-D-aspartate) receptors; eg 6-(4-benzylpiperidin-1-carbonyl)-1,5-dihydro-oxazolo[4,5-f]indole-2-one
05/26/2005US20050113359 NMDA (N-methyl-D-aspartate) receptors; eg 1-[4-(4-fluoro-benzyl)-piperidin-1-yl]-1-(6-hydroxy-1H-indole-2-yl)methanone
05/26/2005US20050113344 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
05/26/2005CA2545435A1 Hydroxy piperidine derivatives to treat gaucher disease
05/26/2005CA2545433A1 Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
05/26/2005CA2544981A1 4-phenyl piperidine sulfonyl glycine transporter inhibitors
05/26/2005CA2543913A1 Benzylether amine compounds useful as ccr-5 antagonists
05/26/2005CA2541949A1 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
05/26/2005CA2534342A1 Amino acid prodrugs
05/25/2005EP1533314A1 Process for producing cyclic thioether and synthetic intermediate thereof
05/25/2005EP1533310A1 Isonipecotamides for the treatment of integrin-mediated disorders
05/25/2005EP1533298A1 3-aminopyrrolidone derivatives
05/25/2005EP1532124A1 Novel compounds
05/25/2005EP1532111A1 2,5-disubstituted 3-mercaptopentanoic acid
05/25/2005EP1532110A1 Industrial process for the synthesis of isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine dicarboxylate (nisoldipine)
05/25/2005EP1531879A1 Use of organic compounds
05/25/2005EP1531821A2 Sulphonylpiperidine derivatives containing an alkenyl or alkynyl moiety for use as matrix metalloproteinase inhibitors
05/25/2005EP1140814B1 Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
05/25/2005EP0946511B1 Novel compounds with analgesic effect
05/25/2005CN1620435A 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
05/25/2005CN1203058C Piperidine derivatives and drugs containing these derivatives as active ingredient
05/25/2005CN1203047C Biaryl ether derivatives useful as monoamine reuptake inhibitors
05/25/2005CN1202824C Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for preparing medicine for treating hepatitis virus infection
05/24/2005US6897323 Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same
05/24/2005US6897234 Asthma therapy; antiallergens; antiinflammatory agents
05/24/2005US6897210 Anticancer agents; antiarthritic agents
05/24/2005CA2157792C N-(3-piperidinyl-carbonyl)-beta-alanine derivatives as paf antagonists
05/19/2005WO2005044799A1 Dipeptide-analogue synthesis
05/19/2005WO2005044798A1 Industrial method for separation and purification of fentanyl by reverse phase preparative chromatography
05/19/2005WO2005044797A1 Allosteric modulators of metabotropic glutamate receptors
05/19/2005WO2005028436A3 Thalidomide analogs as tnf-alpha modulators
05/19/2005WO2005028429A3 Haloalkyl containing compounds as cysteine protease inhibitors
05/19/2005WO2005012220A9 Cycloalkylidene compounds as modulators of estrogen receptor
05/19/2005WO2004092100A8 Indene derivatives as pharmaceutical agents
05/19/2005US20050107613 Novel pharmaceutical salt of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine (Donepezil)
05/19/2005US20050107434 heterocyclic amines such as 1-Cyclopentyl-4-{2-[5-(4-methanesulfonylphenyl)[1,2,4]oxadiazol-3-yl]ethyl}piperidine and salts, used as histamine-H3 receptor antagonists for treatment of nervous system, cardiovascular , respiratory system, gastrointestinal system and endocrinological system disorders
05/19/2005US20050107432 such as 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-ylidene]methylpiperidine, used for treating nervous system, neurodegenerative and/or psychological disorders
05/19/2005US20050107428 Antiinflammatory agents; autoimmune diseases; rheumatic diseases; anticholesterol agents; cardiovascular disorders
05/19/2005US20050107397 Sulfonamide derivatives as d3-receptor agonists
05/19/2005US20050107384 to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a HDAC in a biological sample comprising detecting or measuring the formation of a complex between a labelled compound as defined in claim (I) and a HDAC
05/19/2005US20050107383 such as 2-(2-propenylthio)-4-(4-trifluoromethylphenyl)benzonitrile; for farm and garden pests including mites, lepidopterans, hemipterans, hymenopterans, orthopterans and isopterans; antiviral agent, fungicide, herbicide
05/19/2005US20050107381 e.g. 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-pyridin-2-yl-butyramide; inhibiting A beta -production; Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis, cerebral amyloid angiopathy, a prion-mediated disease, inclusion body myositis, stroke, multiple sclerosis and Down's Syndrome
05/19/2005US20050107257 Derivatives of (1-benzyl-piperidine-4-yl)-diphenyl-methanol and their use as pesticide
05/19/2005US20050106709 First reactive functional group used to provide attachment to a surface of a substrate, second reactive functional group is a N-sulfonyldicarboximide group reacted with an amine-containing material, to form a connector group between the substrate and amine containing material (protein, peptide, dna rna)
05/19/2005US20050104042 Process for the synthesis of amine ethers from secondary amino oxides
05/19/2005CA2544748A1 Allosteric modulators of metabotropic glutamate receptors
05/19/2005CA2544195A1 Industrial method for separation and purification of fentanyl by reverse phase preparative chromatography
05/19/2005CA2543884A1 Dipeptide-analogue synthesis
05/18/2005EP1531151A1 A process for the preparation of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl] methyl piperidine hydrochloride (donepezil hcl)
05/18/2005EP1530564A2 Compounds derived from aryl carbamates, preparation thereof and uses of same
05/18/2005EP1263724B1 Novel compounds
05/18/2005EP1259484B1 Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion
05/18/2005CN1617865A Phenylalkynes
05/18/2005CN1617852A Alpha-(n-sulphonamido)acetamide derivatives as beta-amyloid inhibitors
05/18/2005CN1617743A New pharmaceutical combinations for nos inhibitors
05/18/2005CN1617718A N-aryl-N'-arylcycloalkyl-urea derivatives as MCH antagonists for the treatment of obesity
05/18/2005CN1616432A Compound, its use and pharmaceutical compositions comprising same
05/18/2005CN1615861A (1s, 2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylipiperidin-1-yl)-1-propanolmethanesulfonate trihydrate
05/18/2005CN1202085C Preparation of sterically hindered amine ethers
05/18/2005CN1202050C Polymerization inhibiting method for ethenyl chemical compound
05/18/2005CN1201735C Mycobacterial inhibitors
05/17/2005US6894191 Reacting arylamine with aromatic halide in presence of catalyst and base
05/17/2005US6894072 Compounds as NS3-serine protease inhibitors of hepatitis C virus
05/17/2005US6894063 Drugs for treating metabolic and eating disorders, diabetes
05/17/2005US6894005 Heterocyclic compound containing phenyl groups; postemergence herbicides
05/17/2005US6892568 Noise detection system and method
05/17/2005CA2174969C Short-acting dihydropyridines
05/17/2005CA2103845C 9-[(substituted glycyl)-amido]-6-demethyl-6-deoxytetracyclines
05/12/2005WO2005042521A2 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
05/12/2005WO2005042513A1 Phenyl carboxamide and sulfonamide derivatives for use as 11-beta-hydroxysteroid dehydrogenase
05/12/2005WO2005042489A1 N-substituted benzene sulfonamides
05/12/2005WO2005042487A1 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
05/12/2005WO2005042486A1 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
05/12/2005WO2005042485A1 Acid added salts of amlodipine
05/12/2005WO2005041875A2 Dopamine-, norepinephrine- and serotonin- transporter- selective heterocyclic compounds and their therapeutic applications
1 ... 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 ... 380